BARDA has recently unveiled significant updates to its BAA, emphasizing a more refined and responsive approach to public health preparedness. Amendment 4 introduces crucial changes to the Areas of Interest designed to align BARDA’s efforts with the evolving landscape of global health threats.
BARDA Issues Amendment 4 to BAA for Medical Countermeasures R&D Read More »
The Defense Advanced Research Projects Agency is hosting an Industry Day for the B-SAFE (Broad-Spectrum Antagonists for Editors) program on June 28, 2024, in Arlington, VA, with a webinar option available. This event is pivotal for those in the science and technology communities, including industry, academia, and government, who are interested in advancing gene editing technologies.
Join DARPA’s B-SAFE Industry Day for Groundbreaking Advances in Gene Editing Inhibitors Read More »
At EverGlade Consulting, we are always on the lookout for new funding opportunities that can help our clients advance their research and development goals. Today, we’re excited to inform you about a new Request for Applications (RFA) from the National Institutes of Health (NIH): RFA-HG-24-004.
The Biomedical Advanced Research and Development Authority (BARDA) has recently unveiled significant updates to its Broad Agency Announcement (BAA), emphasizing a more refined and responsive approach to public health preparedness. Amendment 3, in particular, brings crucial changes to the Areas of Interest (AOIs) that are designed to align BARDA’s efforts with the evolving landscape of global health threats.
BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D Read More »
It seems that there may be a new Valley of Death on the horizon of COVID therapeutic development. Earlier this month (9 JUL) NIAID posted a Funding Opportunities Announcement soliciting proposals related to COVID therapeutic development through their Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program (RFA-AI-21-050: Antiviral Drug Discovery (AViDD) Centers
A New Valley of Death? by Eric Jia-Sobota Read More »
Earlier this month the Army Contracting Command published an amendment to solicitation W911QY-20-S-C001 related to Area of Interest 5, oral antiviral therapeutics. This is a procurement solicitation and specifically the USG is looking for direct-acting antivirals for COVID-19 high-risk patients. Successful offerors will be able to deliver 500,000 treatment courses of the anti-viral within eight
COVID-19 Antiviral Therapeutics Procurement by Eric Jia-Sobota Read More »
For the past 18 months companies have been confused and frustrated by the shifting USG policies regarding the development of therapeutics as part of the COVID-19 response. BARDA was back and forth as parts of the BAA were suspended, unsuspended, and resuspended. The American rescue Plan legislation was passed about six months ago and although
New Opportunity for COVID Therapeutics by Eric Jia-Sobota Read More »
The Joint Army Contracting Command and the Joint COVID Response Division (ACC-JCRD) recently published a solicitation seeking Commercial Solutions to decrease US reliance on fragile global supply chains and increase preparedness for future pandemics. The solicitation seeks to establish, expand, and accelerate the availability of domestically-produced supplies in several different areas, some of which may
ACC-JCRD seeking Commercial Solutions by Eric Jia-Sobota Read More »
Executive Summary BARDA’s suspension of funding for COVID-19 therapeutics risks repeating mistakes of past pandemics as it may cause industry to pull out of the development space, experts say. Industry sources are concerned the Biden administration is focusing on funding NIH at the expense of BARDA. The Biomedical Advanced Research and Development Authority quietly suspended
BARDA Funding Freeze Risks Companies Abandoning COVID Therapeutic Work Read More »
The DPA Title III program just received an additional $10B in the recovery legislation that was recently passed. The DPA program is administered by the US Air Force and more information can be found here beta.SAM.gov. The solicitation is open until JUL 2024 to offerors that meet the requirements of the Defense Production Act of
DPA Funding Opportunity by Eric Jia-Sobota Read More »
Recently we became aware of two new opportunities for federal funding through HHS and DoD. We believe these may present exciting new avenues for companies that work in these areas. First, BARDA just posted two new RFIs with a response deadline of April 23, 2021. Links to these are here: beta.SAM.gov | Search – Expansion
New BARDA RFIs Released by Eric Jia-Sobota Read More »
Recently, the Coalition for Epidemic Preparedness Innovations (CEPI) published a call for proposals that is open from 28 JAN 2021 to 28 MAY 2021 and can be found here [CEPICfPCallText.pdf]. Trials that expand access in low and middle income countries is strongly encouraged. The objective is to expand access to vaccines that are already in
CEPI Funding Opportunity by Eric Jia-Sobota Read More »
